R波相关振动法血压测量

为了提高振地血压测量的准确性，提出了一咱基于心电Ｒ波与血压振动波之间相关性，识别振动信号的一种抗干扰方法＝－Ｒ波相关法，结合振动波形特征识别，该方法可有效地提取信号，消除干扰影响，该算法已在１６位８０９８单片机上实现，本文同时给出了程序的详细流程图。     

Morpheaform Basal Cell Carcinoma in African Americans

Background. Although it has been established that basal cell carcinoma is an uncommon diagnosis in black patients, the morpheaform subtype is very rare among these individuals.
Objective. The objective is to present two cases of morpheaform basal cell carcinoma in African-American patients.
Methods. This is a case series and a literature review using the Ovid Medline Database. Key words used in the search include "basal cell carcinoma,""African American,""black,""African,""negros,""morpheaform,""sclerosing,""fibrosing," and "scar-like basal cell carcinoma." The Ovid Medline Database was searched from 1966 to present and was restricted to the English language.
Results. A review of the Emory Dermatology clinic charts from 1989 to 2004 revealed two black patients with morpheaform basal cell carcinomas.
Conclusions. Although extremely rare, morpheaform pattern basal cell carcinoma must be considered in the differential diagnosis for black patients presenting with nonhealing lesions.     

母亲苯丙酮尿症后代的脑MRI表现

目的 提高对母亲苯丙酮尿症(MPKU)后代脑MRI表现的认识。资料与方法 报告2例生化及临床检查证实为MPKU双胞胎的．MRI改变，并复习文献。结果 文中2例表现与文献报道不一致．与苯丙酮尿症患儿的表现相似。常规T2WI及FLAIR均显示室周白质、侧脑室三角区、半卵圆中心条片状高信号。弥散加权成像(DWI)除更清楚地显示上述改变外，尚显示双侧内囊后肢及胼胝体压部信号增高。结论 常规T2WI及FIJAIR上可显示MPKU后代脑白质异常，DWI可提供更多诊断依据。     

AmpC酶在主要肠杆菌科和非发酵菌中的携带率及耐药性

目的：调查主要肠杆菌科细菌和非发酵菌产AmpC酶和ESBLs的状况及对常用抗菌药物的耐药性，指导临床合理用药。方法：常规培养分离细菌，应用VTTEK微生物自动分析仪和API鉴定系统鉴定病原菌；药敏试验采用K-B纸片扩散法；AmpC酶检测采用三维试验法；ESBLs检测采用双纸片确认试验。结果：主要肠杆菌科细菌产AmpC酶和ESBLs的阳性率分别为18．9％，52．8％，其中以大肠杆菌、肺炎克雷伯、产酸克雷伯、阴沟肠杆菌为主，同时产2种酶的菌株占15．4％；绿脓杆菌产AmpC酶和ESBLs酶的阳性率分别为18．2%，，42．0％，同时产2种酶的菌株占13．6％；不动杆菌的产酶率均在8．0％以下,产酶菌的耐药率高于非产酶菌，除绿脓杆菌外，产AmpC酶菌株的耐药率高于产ESBLs菌株．主要肠杆菌科细菌对泰能(IMP)的敏感性为99．5%，而对舒普深(CPZ)的耐药率平均为13．8％；非发酵菌对IMP，马斯平(FEP)、CPZ的耐药率平均分别为20．4％，44．3％，18．6％.结论：主要肠杆菌科细菌的产酶率高于非发酵菌，产AmpC酶的菌株已近20．0%，应引起临床的高度重视；绿脓杆菌产ES-BLs的菌株也较高，也应该加强监控．对产酶菌引起感染的治疗应根据细菌药敏试验结果，合理选择有效的抗菌药物联合治疗；对重症感染患的治疗应根据药敏试验结果重点应用泰能或舒普深治疗。     

CLOTBUST: Design of a Randomized Trial of Ultrasound-Enhanced Thrombolysis for Acute Ischemic Stroke

BACKGROUND: Intravenous tissue plasminogen activator (TPA) therapy can be monitored with 2 MHz transcranial Doppler (TCD). This article describes the design of CLOTBUST (combined lysis of thrombus in brain ischemia using transcranial ultrasound and systemic TPA), the first prospective international multicenter randomized clinical trial of noninvasive externally applied ultrasound to enhance systemic thrombolysis in human stroke. SUBJECTS: Patients with acute ischemic stroke eligible for intravenous TPA therapy within 3 hours of symptom onset who have detectable middle cerebral artery occlusion on a prebolus TCD are included in this trial. All patients receive standard 0.9 mg/kg TPA therapy. Patients are randomized (1:1) to either 2 hours of continuous monitoring with TCD or placebo monitoring. FDA-approved portable diagnostic TCD equipment and standard headframes (Marc series, Spencer Technologies, Seattle, WA) are used. Output of TCD units is set at 100% power achievable at depths of insonation that display the worst TIBI flow grade signals. METHODS AND END-POINTS: Acute MCA occlusion on prebolus TCD is defined as thrombolysis in brain ischemia (TIBI) flow grades 0-3. Treating physicians are blinded to randomization assignment, and certified scorers measure stroke severity using the National Institute of Health Stroke Scale (NIHSS). Safety of continuous TCD monitoring is determined by rates of symptomatic (NIHSS score increase by 4+ points) intracerebral hemorrhage within 72 hours after initial symptom onset. Potential enhancement of TPA therapy will be determined using combined primary end-point of early complete recanalization on TCD (TIBI flow grades 4-5), dramatic recovery (NIHSS < or = 3 points), or decline in the NIHSS > or = 10 points repeatedly measured every 30 minutes within 2 hours after TPA bolus. Other end-points include recovery at 24 hours and 3 months, modified Rankin scores (mRS) are obtained at 90 days, and favorable outcome is determined as NIHSS or mRS scores 0-1. CONCLUSIONS: The aim of phase II CLOTBUST trial is to determine the rates of early complete recanalization and dramatic/early clinical recovery in TPA + TCD and TPA groups. The sample size is set at 126 patients since a medium effect size (.50) is anticipated for TPA + TCD group vs TPA alone to achieve combined primary end-point.     

热缺血供体同种异体犬肺移植术后早期肺功能的观察

目的　观察犬热缺血供体同种异体肺移植术后早期移植肺功能情况。方法　采用室温下热缺血 3 0min、LPD液灌注后 4℃保存 2 5h时的供肺 ,行右肺同种异体移植手术 7例 ,术前及监测恢复灌注 0 5 ,1,2及 4h的动脉血氧分压 (PaO2 )、肺动态顺应性 (Cdyn)、平均肺动脉压 (mPAP)、肺毛细血管楔压 (PCWP)和心输出量的变化 (CO)。结果　所有受体犬在观察期间均存活。恢复灌注 4h内的肺功能各指标变化差异无显著性 (P >0 0 5 ) ,或者虽然有统计学差异 ,但仍有较好的绝对水平。结论　热缺血 3 0min低温保存 2 5h的供肺可以维持生命 ,恢复灌注后 ,受缺血再灌注损伤的影响 ,在灌注后一段时间内 ,供肺功能下降 ,但仍可较好支持生命。